Open access · CC-BY
via OpenAlex
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
Philip S.J. Weston, Teresa Poole, Natalie Sarah Ryan, Akshay Nair, Yuying Liang, Kirsty Macpherson, Ronald Druyeh, Ian B. Malone, R. Laila Ahsan, Hugh Pemberton, Jana Klímová, Simon Mead, Kaj Blennow, Martin N. Rossor, Jonathan M. Schott
Neurology · 2017 · ▲ 253 citations
Abstract
Objectives: To investigate whether serum neurofilament light (NfL) concentration is increased in familial Alzheimer disease (FAD), both pre and post symptom onset, and whether it is associated with markers of disease stage and severity. Methods: We recruited 48 individuals from families with PSEN1 or APP mutations to a cross-sectional study: 18 had symptomatic Alzheimer disease (AD) and 30 were asymptomatic but at 50% risk of carrying a mutation. Serum NfL was measured using an ultrasensitive immunoassay on the single molecule array (Simoa) platform. Cognitive testing and MRI were performed; 33 participants had serial MRI, allowing calculation of atrophy rates. Genetic testing established mutation status. A generalized least squares regression model was used to compare serum NfL among symptomatic mutation carriers, presymptomatic carriers, and noncarriers, adjusting for age and sex. Spearman coefficients assessed associations between serum NfL and (1) estimated years to/from symptom onset (EYO), (2) cognitive measures, and (3) MRI measures of atrophy. Results: Nineteen of the asymptomatic participants were mutation carriers (mean EYO −9.6); 11 were noncarriers. Compared with noncarriers, serum NfL concentration was higher in both symptomatic (p < 0.0001) and presymptomatic mutation carriers (p = 0.007). Across all mutation carriers, serum NfL correlated with EYO (ρ = 0.81, p < 0.0001) and multiple cognitive and imaging measures, including Mini-Mental State Examination (ρ = −0.62, p = 0.0001), Clinical Dementia Rating Scale sum of boxes (ρ = 0.79, p < 0.0001), baseline brain volume (ρ = −0.62, p = 0.0002), and whole-brain atrophy rate (ρ = 0.53, p = 0.01). Conclusions: Serum NfL concentration is increased in FAD prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1212/wnl.0000000000004667
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Weston, P.S., Poole, T., Ryan, N.S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I.B., Ahsan, R.L., Pemberton, H., Klímová, J., Mead, S., Blennow, K., Rossor, M.N., Schott, J.M., Zetterberg, H., & Fox, N.C. (2017). Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. <em>Neurology</em>. https://doi.org/10.1212/wnl.0000000000004667
Vancouver
Weston PS, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017. doi:10.1212/wnl.0000000000004667.
BibTeX
@article{philip2017Serumn,
title = {Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration},
author = {Philip S.J. Weston and Teresa Poole and Natalie Sarah Ryan and Akshay Nair and Yuying Liang and Kirsty Macpherson and Ronald Druyeh and Ian B. Malone and R. Laila Ahsan and Hugh Pemberton and Jana Klímová and Simon Mead and Kaj Blennow and Martin N. Rossor and Jonathan M. Schott and Henrik Zetterberg and Nick C. Fox},
journal = {Neurology},
year = {2017},
doi = {10.1212/wnl.0000000000004667},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Seoul National University Hospital 2014
Open access · US-GOV
Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease
Dementia & Neuropsychologia 2016
Open access · CC-BY
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Chinese PLA General Hospital 2025
Open access · US-GOV
Ultra-high Field Multimodal and Multinuclear Neuroimaging Cohort Study of Alzheimer's Disease
2022
Open access · CC-BY
Decision letter: Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex
2014
Citation only
Effects of genetic variation on the dynamics of neurodegeneration in Alzheimer's disease
Centre Hospitalier de Saint-Denis 2022
Open access · US-GOV